ReviewBiomolecules2026
Sliding into Place: The Lymphatic Vessel Endothelial Hyaluronan Receptor LYVE-1 and Its Role as a Mediator of Cell Entry and Trafficking in the Lymphatics.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Hyaluronan (HA) receptors are expressed in a wide variety of different tissues and have long been known to support the critical cellular functions of adhesion and motility, in addition to a range of different physiological and pathological processes, including immunity, inflammation and tumour metastasis. In recent years, LYVE-1, an HA receptor largely but not exclusively restricted to the endothelia of lymphatic capillaries, has been shown to mediate the entry of immune cells through lymphatic endothelial junctions by engaging with their surface HA glycocalyx, itself anchored to the immune cell membrane by the closely related receptor CD44. Although similar to CD44 in primary sequence, LYVE-1 is functionally distinct, with a mutually exclusive pattern of tissue expression and a marked dependence on avidity for engagement with the long chains of HA-achieved primarily through receptor clustering. Here, we review key data that have defined the in vitro and in vivo functions of LYVE-1, including recent high-resolution crystal structures that have revealed its unusual and reversible "sliding" mode of interaction with HA, as distinct from the conventional "sticking" interaction in CD44. Lastly, we consider the emerging functions of LYVE-1 in sites beyond the lymphatics, namely tissue-resident macrophages and the specialised blood vessels of certain organs, and its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.